Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Utah: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 5 | 312 | 41% |
| 2020 | 9 | 396 | 44% |
| 2021 | 13 | 532 | 48% |
| 2022 | 14 | 576 | 51% |
| 2023 | 17 | 629 | 54% |
| 2024 | 21 | 682 | 57% |
| 2025 from claims | – | 743 600–872 | 59% |
| 2026 forecast | – | 808 633–1,015 | 60% |
| 2027 forecast | – | 881 653–1,164 | 61% |
| 2028 forecast | – | 959 679–1,323 | 62% |
| 2029 forecast | – | 1,043 709–1,496 | 62% |
| 2030 forecast | – | 1,135 744–1,684 | 63% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 68% of the cases CMS names in Utah; 14 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 71% inpatient hospital, 12% hospital outpatient, 16% office. The share outside the hospital has moved +12 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~810 | ~590 | ~90 | ~130 |
| 2027 · ~880 | ~640 | ~94 | ~140 |
| 2028 · ~960 | ~700 | ~100 | ~150 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 73% (71% in 2025), hospital outpatient about 10% (12% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 227 | 10,060+12%/yr | +12%/yr | 2.6 | 33% | 20,000 in 2030+12%/yr |
| Arizona | 106 | 4,739+15%/yr | +15%/yr | 5.6 | 41% | 7,950 in 2030+9%/yr |
| Washington | 46 | 2,007+11%/yr | +11%/yr | 2.3 | 2% | 3,420 in 2030+9.3%/yr |
| Colorado | 39 | 1,871+12%/yr | +12%/yr | 3.3 | 4% | 4,220 in 2030+15%/yr |
| Idaho | 16 | 740+15%/yr | +15%/yr | 3.2 | 0% | 1,470 in 2030+12%/yr |
| Oregon | 19 | 718+9.3%/yr | +9.3%/yr | 1.5 | 5% | 1,330 in 2030+11%/yr |
| Nevada | 14 | 673+17%/yr | +17%/yr | 2.0 | 16% | 1,740 in 2030+17%/yr |
| New Mexico | 5 | 431+11%/yr | +11%/yr | 1.6 | 2% | 1,040 in 2030+16%/yr |
| Montana | 12 | 395+13%/yr | +13%/yr | 1.9 | 0% | 760 in 2030+11%/yr |
| Alaska | 4 | 103+2.1%/yr | +2.1%/yr | 0.8 | 39% | 120 in 2030+2.5%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| EP ablation | 20 | 1,253+6.8%/yr | +6.8%/yr | 4.81.6× | 0% | 2,180 in 2030+9.7%/yr |
| Pacemaker, ICD & CRT implantation | 22 | 921−2.8%/yr | −2.8%/yr | 4.41.1× | 0% | 900 in 2030−0.4%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Utah · Every state · Compare with California
Boston Scientific leads with 98% of company spending on these surgeons in 2025, +2 pts on 2024.
In 2025, 5 companies reported engagement with Utah’s surgeons worth $151K in consulting, speaking, meals and travel tied to these products, about $7,177 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.